Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23913125.
- Also identified by DOI 10.1038/nm.3261 and PMC identifier 4153471.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mitochondrial diseases are commonly caused by mutated mitochondrial DNA (mtDNA), which in most cases coexists with wild-type mtDNA, resulting in mtDNA heteroplasmy. We have engineered transcription activator-like effector nucleases (TALENs) to localize to mitochondria and cleave different classes of pathogenic mtDNA mutations. Mitochondria-targeted TALEN (mitoTALEN) expression led to permanent reductions in deletion or point-mutant mtDNA in patient-derived cells, raising the possibility that these mitochondrial nucleases can be therapeutic for some mitochondrial diseases.
Medical subject headings
- DNA, Mitochondrial
- Deoxyribonucleases, Type II Site-Specific
- Mitochondrial Diseases
- Osteosarcoma